PDCD1 and neoplasm: In recent years, the treatment landscape of lung cancer has undergone a paradigm shift with the introduction of immune-checkpoint inhibitors (ICIs), particularly those targeting the programmed cell death protein 1 (PD-1) and its ligand PD-L1, which enhance anti-tumor immune responses.